Control of immune cell entry through the tumour vasculature: A missing link in optimising melanoma immunotherapy?

Clinical and Translational Immunology

Volumn 6, Issue 3, 2017, Pages

  Tan, Lih Yin ^a   Martini, Carmela ^a   Fridlender, Zvi G ^b   Bonder, Claudine S ^a   Brown, Michael P ^a,c,d   Ebert, Lisa M ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CELL ADHESION MOLECULE; CHEMOKINE;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL HOMING; CUTANEOUS MELANOMA; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; LEUKOCYTE FUNCTION; LOW ENERGY RADIATION; METASTASIS POTENTIAL; METASTATIC MELANOMA; MONOCYTE; NEUTROPHIL; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; THROMBOCYTE FUNCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

EID: 85028529620     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2017.7     Document Type: Review

References (100)

1. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348: 69-74.
2. Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? Eur J Cancer 2016; 62: 76-85.
3. Topalian Suzanne L, Drake Charles G, Pardoll Drew M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450-461.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
5. Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM et al. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort. J Clin Oncol 2016; 34: (suppl; abstr 9506).
6. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348: 62-68.
7. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-4557.
8. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther 2016; 24: 1135-1149.
9. Blank CU, Haanen JB, Ribas A, Schumacher TN. The 'cancer immunogram'. Science 2016; 352: 658-660.
10. Ladányi A, Somlai B, Gilde K, Fejös Z, Gaudi I, Tímár J. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 10: 521-530.
11. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C et al. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005; 104: 1246-1254.
12. van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 2008; 123: 609-615.
13. Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti I et al. Utility of tumour-infiltrating CD25+ FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 2007; 18: 1115-1122.
14. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27: 1-7.
15. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 2013; 35: 585-600.
16. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int J Cancer 2000; 85: 182-188.
17. Varney ML, Johansson SL, Singh RK. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 2005; 15: 417-425.
18. Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A et al. BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth. Clin Cancer Res 2015; 21: 1652-1664.
19. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L et al. Polarization of tumorassociated neutrophil phenotype by TGF-β: 'N1' versus 'N2' TAN. Cancer Cell 2009; 16: 183-194.
20. Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother 2013; 62: 1745-1756.
21. Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003; 103: 335-343.
22. Jensen TO, Schmidt H, Möller HJ, Donskov F, Höyer M, Sjoegren P et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012; 118: 2476-2485.
23. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005; 93: 273-278.
24. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 2015; 21: 5453-5459.
25. Zaragoza J, Caille A, Beneton N, Bens G, Christiann F, Maillard H et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol 2016; 174: 146-151.
26. Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Görgens A et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013; 133: 1653-1663.
27. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014; 63: 247-257.
28. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72: 876-886.
29. Vestweber D. How leukocytes cross the vascular endothelium. Nat Rev Immunol 2015; 15: 692-704.
30. Nooijen PT, Westphal JR, Eggermont AM, Schalkwijk C, Max R, de Waal RM et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol 1998; 152: 679-682.
31. Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181: 811-816.
32. Weishaupt C, Munoz KN, Buzney E, Kupper TS, Fuhlbrigge RC. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007; 13: 2549-2556.
33. Corey DM, Rinkevich Y, Weissman IL. Dynamic patterns of clonal evolution in tumor vasculature underlie alterations in lymphocyte-endothelial recognition to foster tumor immune escape. Cancer Res 2016; 76: 1348-1353.
34. Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006; 66: 10770-10777.
35. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Bouma-ter Steege JC et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 63: 2322-2329.
36. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121: 2371-2382.
37. Carlos TM. Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukoc Biol 2001; 70: 171-184.
38. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 1996; 148: 1887.
39. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2010; 41: 375-384.
40. Straetemans T, Berrevoets C, Coccoris M, Treffers-Westerlaken E, Wijers R, Cole DK et al. Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment. Mol Ther 2015; 23: 396-406.
41. Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Virchows Arch 2001; 438: 485-491.
42. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14: 28-36.
43. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607-615.
44. Hillen F, Baeten CI, van de Winkel A, Creytens D, van der Schaft DW, Winnepenninckx V et al. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother 2008; 57: 97-106.
45. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie J-J et al. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011; 71: 5678-5687.
46. Uotila LM, Aatonen M, Gahmberg CG. Integrin CD11c/CD18 alpha-chain phosphorylation is functionally important. J Biol Chem 2013; 288: 33494-33499.
47. Yakubenko VP, Yadav SP, Ugarova TP. Integrin αDβ2, an adhesion receptor up-regulated on macrophage foam cells, exhibits multiligand-binding properties. Blood 2006; 107: 1643-1650.
48. Nieminen J, St-Pierre C, Bhaumik P, Poirier F, Sato S. Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J Immunol 2008; 180: 2466-2473.
49. Ebeling O, Duczmal A, Aigner S, Geiger C, Schöllhammer S, Kemshead JT et al. L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to αvβ3 integrin. Eur J Immunol 1996; 26: 2508-2516.
50. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 2006; 168: 1666-1675.
51. Demotte N, Wieers G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumorinfiltrating lymphocytes and favors tumor rejection in mice. Cancer Res 2010; 70: 7476-7488.
52. Mikucki M, Fisher D, Matsuzaki J, Skitzki J, Gaulin N, Muhitch J et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 2015; 6: 7458.
53. González-Martín A, Gómez L, Lustgarten J, Mira E, Mañes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4+ and CD8+ T cells. Cancer Res 2011; 71: 5455-5466.
54. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AEI, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003; 63: 8360-8365.
55. Hong M, Puaux A-L, Huang C, Loumagne L, Tow C, Mackay C et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71: 6997-7009.
56. Clancy-Thompson E, Perekslis TJ, Croteau W, Alexander MP, Chabanet TB, Turk MJ et al. Melanoma induces, and adenosine suppresses, CXCR3-cognate chemokine production and T-cell infiltration of lungs bearing metastatic-like disease. Cancer Immunol Res 2015; 3: 956-967.
57. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Bröcker EB, Gillitzer R. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol 1999; 189: 552-558.
58. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-3085.
59. Ji R-R, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J et al. An immuneactive tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61: 1019-1031.
60. Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013; 109: 2412-2423.
61. Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004; 64: 7697-7701.
62. Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM et al. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest 2016; 126: 921-937.
63. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001; 166: 6483-6490.
64. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007; 127: 2031-2041.
65. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208: 1949-1962.
66. Jablonska J, Wu CF, Andzinski L, Leschner S, Weiss S. CXCR2-mediated tumorassociated neutrophil recruitment is regulated by IFN-β. Int J Cancer 2014; 134: 1346-1358.
67. Van Coillie E, Van Aelst I, Wuyts A, Vercauteren R, Devos R, De Wolf-Peeters C et al. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. Am J Pathol 2001; 159: 1405-1414.
68. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006; 125: 209-216.
69. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000; 190: 430-436.
70. Zhou S-L, Dai Z, Zhou Z-J, Wang X-Y, Yang G-H, Wang Z et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 2012; 56: 2242-2254.
71. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72: 3091-3098.
72. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335-350.
73. Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA 2014; 111: E3053-E3061.
74. Gil-Bernabé AM, Ferjančič Š, Tlalka M, Zhao L, Allen PD, Im JH et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012; 119: 3164-3175.
75. Zuchtriegel G, Uhl B, Puhr-Westerheide D, Pörnbacher M, Lauber K, Krombach F et al. Platelets guide leukocytes to their sites of extravasation. PLoS Biol 2016; 14: e1002459.
76. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520: 373-377.
77. Helfrich I, Schadendorf D. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance? Mol Oncol 2011; 5: 137-149.
78. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. FASEB J 2015; 29: 227-238.
79. Wu X, Giobbie-Hurder A, Liao X, Lawrence DP, McDermott DF, Zhou J et al. VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma. Cancer Immunol Res 2016; 4: 858-868.
80. Ganss R, Ryschich E, Klar E, Arnold B, Hämmerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62: 1462-1470.
81. Klug F, Prakash H, Huber Peter E, Seibel T, Bender N, Halama N et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24: 589-602.
82. Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 2015; 26: 798-803.
83. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF et al. Selective BRAF Inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-1394.
84. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19: 393-403.
85. Amin A, Lawson DH, Salama AKS, Koon HB, Guthrie T, Thomas SS et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer 2016; 4: 44.
86. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014; 2: 643-654.
87. Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro. J Immunother 2015; 38: 12-23.
88. Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res 2014; 4: 172-181.
89. Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W et al. Facilitating T Cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 2016; 29: 285-296.
90. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M et al. Transduction of tumorspecific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010; 16: 5458-5468.
91. Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE et al. Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int J Cancer 2011; 129: 847-858.
92. Fridlender ZG, Jassar A, Mishalian I, Wang LC, Kapoor V, Cheng G et al. Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 2013; 108: 1288-1297.
93. Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G et al. Systemic blockade of transforming growth factor-β signaling augments the efficacy of immunogene therapy. Cancer Res 2008; 68: 10247-10256.
94. Hendrix MJC, Seftor EA, Seftor REB, Chao J-T, Chien D-S, Chu Y-W. Tumor cell vascular mimicry: novel targeting opportunity in melanoma. Pharmacol Ther 2016; 159: 83-92.
95. Yang JP, Liao YD, Mai DM, Xie P, Qiang YY, Zheng LS et al. Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis 2016; 19: 191-200.
96. Schnegg CI, Yang MH, Ghosh SK, Hsu M-Y. Induction of vasculogenic mimicry overrides VEGF-A silencing and enriches stem-like cancer cells in melanoma. Cancer Res 2015; 75: 1682-1690.
97. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002; 118: 915-922.
98. Denton KJ, Stretch JR, Gatter KC, Harris AL. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 1992; 167: 187-191.
99. Langer HF, Orlova VV, Xie C, Kaul S, Schneider D, Lonsdorf AS et al. A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis. Cancer Res 2011; 71: 4096-4105.
100. Dunleavey JM, Xiao L, Thompson J, Kim MM, Shields JM, Shelton SE et al. Vascular channels formed by subpopulations of PECAM1+ melanoma cells. Nat Commun 2014; 5: 5200.